Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 46 peer-reviewed journal articles Updated
Oncology

Understanding MALT Lymphoma: A Foundation for Patients

At a Glance

MALT lymphoma is a slow-growing, highly treatable form of non-Hodgkin lymphoma that starts in the body's immune tissues, most commonly the stomach. Because it is often triggered by chronic infections like H. pylori, it can sometimes be cured simply with targeted antibiotics.

Hearing the word lymphoma (a cancer of the lymphatic system) is naturally frightening, but MALT lymphoma is a unique and highly manageable condition [1]. Unlike many other cancers, it is often considered more of a chronic, slow-growing illness than an immediate threat. It is classified as an indolent (slow-growing) B-cell cancer, meaning it typically develops over many years rather than weeks [1]. Most importantly, for many patients, MALT lymphoma has an excellent long-term survival rate and may even be cured by treating an underlying infection [2][3].

Understanding the “MALT” in MALT Lymphoma

MALT stands for Mucosa-Associated Lymphoid Tissue. While most lymphomas start in the lymph nodes, MALT lymphoma starts in the soft linings (mucosa) of organs where the body’s immune system is active [4].

The body normally develops these immune tissues to fight off long-term irritation or infection. However, if the immune cells stay “on” for too long due to chronic inflammation, they can eventually turn into cancer [3][4]. Common sites where this occurs include:

  • The Stomach: The most frequent location, often triggered by the H. pylori bacteria [3].
  • The Eyes: Specifically the tissues around the eye (ocular adnexa), sometimes linked to Chlamydia infections [4].
  • Salivary Glands: Often associated with autoimmune conditions like Sjögren’s syndrome [4].
  • Lungs and Thyroid: Other areas where chronic inflammation can occur [4].

How Rare Is It?

MALT lymphoma—officially called Extranodal Marginal Zone B-cell Lymphoma—is considered a rare disease, but it is the most common form of marginal zone lymphoma.

  • It accounts for approximately 7% to 8% of all Non-Hodgkin Lymphomas (NHL) [5][6].
  • Within the category of Marginal Zone Lymphomas, MALT types are the most common [7].

Your Outlook and Prognosis

The prognosis for MALT lymphoma is generally excellent, especially when caught in the early stages [2][1].

Factor Typical Impact on MALT Lymphoma
Growth Speed Very slow (indolent); may stay localized for years [1].
Treatment Response Highly responsive; gastric versions may resolve with targeted antibiotics [3].
Survival Rate Excellent; most patients have a near-normal life expectancy [2][8].
Transformation Rare; in a small number of cases, it can turn into a faster-growing lymphoma [9].

Genetic Markers and Staging

Doctors use specific tests to understand your specific case. One common test looks for a translocation (a genetic swap between chromosomes) called t(11;18) [10]. If this marker is present, it tells the doctor that the lymphoma might be less likely to respond to antibiotics alone and may require other treatments like radiation or medication [11]. Staging is typically performed using the Ann Arbor system or the Lugano system for stomach cases to determine how far the cells have spread [12][13].

Learn More About MALT Lymphoma

01

The Roots of MALT: How Inflammation Drives the Disease

Learn how chronic inflammation, autoimmune conditions, and infections like H. pylori cause MALT lymphoma. Understand the roots of this extranodal disease.

02

Symptoms and Diagnosis: Finding the Answers

Learn the signs of MALT lymphoma and how it is diagnosed. Understand the required tests, including biopsies, H. pylori testing, and imaging like CT scans.

03

Pathology and Staging: Decoding Your Lab Results

Learn how to read your MALT lymphoma pathology report. Discover what CD markers, the t(11;18) translocation, Lugano staging, and MALT-IPI risk scores mean.

04

Treatment and Care: Choosing Your Path

Learn about MALT lymphoma treatment options. Understand when antibiotics for H. pylori, targeted radiation (ISRT), or therapies like rituximab are used.

05

Survivorship and the Long-Term View

Learn about MALT lymphoma survivorship and long-term care. Understand your surveillance schedule, POD24 status, risk of transformation, and what to expect.

Common questions in this guide

What does MALT lymphoma stand for?
MALT stands for Mucosa-Associated Lymphoid Tissue. It refers to a type of lymphoma that starts in the soft linings of organs where the immune system is active, such as the stomach, eyes, or salivary glands.
Is MALT lymphoma curable?
Yes, MALT lymphoma has an excellent prognosis and is often highly treatable. In cases where it is found in the stomach and linked to an H. pylori bacterial infection, it can sometimes be cured with targeted antibiotics alone.
How fast does MALT lymphoma grow?
MALT lymphoma is classified as an indolent or slow-growing cancer. It typically develops over many years rather than weeks, and often stays localized in one area of the body for a long time.
What does a t(11;18) translocation mean for my treatment plan?
The t(11;18) translocation is a specific genetic marker doctors look for in your biopsy. If this marker is present, it indicates that the lymphoma might be less likely to respond to antibiotics alone and may require other treatments like medication or radiation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was the specific anatomical site where my MALT lymphoma was found?
  2. 2.Was my biopsy tested for the t(11;18) translocation, and how does that affect my treatment plan?
  3. 3.Am I being tested for infections like H. pylori, and could treating an infection potentially cure the lymphoma?
  4. 4.What is the stage of my lymphoma, and do we need imaging like a CT or PET/CT to confirm it?
  5. 5.How often will I need follow-up appointments to monitor for any changes or 'transformation' of the cancer?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    MALT lymphoma affecting the oral cavity: a clinical, pathologic and genetic study of MALT1 gene translocation.

    Legarrea JMA, Santos MLD, Rodrigues NG, et al.

    Oral surgery, oral medicine, oral pathology and oral radiology 2025; (140(6)):740-747 doi:10.1016/j.oooo.2025.07.016.

    PMID: 40858407
  2. 2

    Long-Term Clinical Outcomes of Gastric MALT Lymphoma: A Nationwide Multicenter Study in Korea.

    Kim JS, Park JC, Lee JY, et al.

    Frontiers in oncology 2021; (11()):681689 doi:10.3389/fonc.2021.681689.

    PMID: 34722238
  3. 3

    Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.

    Nakamura S, Hojo M

    Journal of clinical medicine 2022; (12(1)) doi:10.3390/jcm12010120.

    PMID: 36614921
  4. 4

    Non-gastric mucosa-associated lymphoid tissue lymphomas: a narrative review of pathogenesis, diagnosis, and treatment strategies.

    Mallick H, Karri V, Dalia S

    Annals of translational medicine 2025; (13(6)):78 doi:10.21037/atm-25-114.

    PMID: 41502427
  5. 5

    Molecular Pathogenesis of MALT Lymphoma.

    Troppan K, Wenzl K, Neumeister P, Deutsch A

    Gastroenterology research and practice 2015; (2015()):102656 doi:10.1155/2015/102656.

    PMID: 25922601
  6. 6

    Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).

    Raderer M, Kiesewetter B, Ferreri AJ

    CA: a cancer journal for clinicians 2016; (66(2)):153-71 doi:10.3322/caac.21330.

    PMID: 26773441
  7. 7

    Characteristics, efficacy, and prognosis analysis of newly diagnosed marginal zone lymphoma.

    Wang H, Zhang Y, Li Z, Bai O

    Frontiers in immunology 2024; (15()):1466859 doi:10.3389/fimmu.2024.1466859.

    PMID: 39376572
  8. 8

    Prognostic outcome of extranodal marginal zone B-cell lymphoma: a nationwide cohort.

    Nam SY, Jo J

    Scientific reports 2025; doi:10.1038/s41598-025-32259-5.

    PMID: 41402369
  9. 9

    A Rare Case of Primary Pulmonary Diffuse Large B-Cell Lymphoma Transformed from Marginal Zone Mucosa-Associated Lymphoid Tissue Lymphoma.

    Kiełbowski K, Kordykiewicz D, Jesionka J, et al.

    Medicina (Kaunas, Lithuania) 2024; (60(6)) doi:10.3390/medicina60060840.

    PMID: 38929457
  10. 10

    Pleural Mucosa-associated Lymphoid Tissue Lymphoma with Trisomy 18.

    Okamoto N, Hayashi E, Tsukino M

    Internal medicine (Tokyo, Japan) 2019; (58(6)):891-892 doi:10.2169/internalmedicine.1780-18.

    PMID: 30449802
  11. 11

    Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results.

    Toyoda K, Maeshima AM, Nomoto J, et al.

    Annals of hematology 2019; (98(7)):1675-1687 doi:10.1007/s00277-019-03671-5.

    PMID: 30923996
  12. 12

    Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT-Lymphoma) of the Intestine: A Single Center Analysis.

    Steinbrecher O, Kiesewetter B, Dolak W, et al.

    Hematological oncology 2025; (43(1)):e70007 doi:10.1002/hon.70007.

    PMID: 39624879
  13. 13

    A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.

    Makita S, Maruyama D, Maeshima AM, et al.

    Asia-Pacific journal of clinical oncology 2020; (16(3)):108-114 doi:10.1111/ajco.13248.

    PMID: 31802636

This page provides educational information about MALT lymphoma and does not replace professional medical advice. Always consult your oncologist or hematologist regarding your specific diagnosis, genetic markers, and treatment plan.

Get notified when new evidence is published on MALT lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.